JAK2 Inhibitors
Santa Cruz Biotechnology now offers a broad range of JAK2 Inhibitors. JAK2 (Janus kinase 2) belongs to the family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK2. JAK2 Inhibitors offered by Santa Cruz inhibit JAK2 and, in some cases, other transcription regulation and cytokine receptor related proteins. View detailed JAK2 Inhibitor specifications, including JAK2 Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
Items 1 to 10 of 29 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Stat3 Inhibitor III, WP1066 | 857064-38-1 | sc-203282 | 10 mg | $132.00 | 72 | |
WP1066 is a JAK2 inhibitor and can reduce JAK2 expression by blocking its signaling. | ||||||
Cucurbitacin I | 2222-07-3 | sc-203010 | 1 mg | $250.00 | 9 | |
Cucurbitacin I inhibits JAK2/STAT3 signaling, potentially decreasing JAK2 expression. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $84.00 $329.00 $223.00 $87.00 | 35 | |
AG490 is a JAK2 inhibitor that can block JAK2 signaling, potentially leading to decreased JAK2 expression. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $156.00 $339.00 | 59 | |
JAK Inhibitor I selectively targets JAK2, characterized by its ability to engage in specific electrostatic interactions that stabilize the enzyme's active conformation. Its unique binding dynamics involve a combination of van der Waals forces and π-π stacking, facilitating a robust affinity for the JAK2 active site. The compound exhibits a distinct reaction kinetics profile, allowing for a controlled modulation of JAK2 activity, which is crucial for understanding its biochemical pathways. | ||||||
AZD1480 | 935666-88-9 | sc-364735 sc-364735A | 5 mg 50 mg | $124.00 $1072.00 | 11 | |
AZD1480 is a JAK2 inhibitor which can block JAK2 signaling, possibly leading to decreased JAK2 expression. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a JAK1/2 inhibitor. By inhibiting JAK2 kinase activity, it may reduce JAK2 protein stability and expression. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö 6976 is a selective inhibitor of JAK2, notable for its unique ability to disrupt the enzyme's dimerization process. This compound engages in specific hydrogen bonding interactions that alter the conformational landscape of JAK2, effectively hindering its signaling pathways. Its kinetic profile reveals a rapid onset of action, with a distinctive allosteric modulation that influences downstream signaling cascades, providing insights into the regulatory mechanisms of cellular responses. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib acts as a selective JAK2 inhibitor, characterized by its unique binding affinity that stabilizes the inactive conformation of the enzyme. This compound exhibits a distinct interaction with the ATP-binding site, leading to competitive inhibition that alters the enzyme's catalytic activity. Its kinetic behavior showcases a prolonged duration of action, with a specific impact on the phosphorylation state of target proteins, thereby influencing cellular signaling dynamics and regulatory networks. | ||||||
Cyt387 | 1056634-68-4 | sc-364733 sc-364733A | 10 mg 50 mg | $214.00 $612.00 | 2 | |
Cyt387 inhibits JAK1/2, potentially leading to reduced JAK2 protein stability and expression. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is a potent JAK2 inhibitor that uniquely disrupts the enzyme's signaling pathways by targeting the ATP-binding pocket. Its binding induces conformational changes that prevent substrate access, effectively modulating downstream signaling cascades. The compound exhibits a rapid onset of action, with a notable impact on the phosphorylation of key regulatory proteins. This selective inhibition alters cellular responses, highlighting its role in fine-tuning intracellular communication and metabolic processes. | ||||||